(QTRX) Quanterix - Ratings and Ratios
Digital Immunoassay Platform, Multiplex Analyzer, Assay Kits, Contract Research
QTRX EPS (Earnings per Share)
QTRX Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 73.1% |
| Value at Risk 5%th | 108% |
| Relative Tail Risk | -10.52% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.61 |
| Alpha | -83.49 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.420 |
| Beta | 1.758 |
| Beta Downside | 1.827 |
| Drawdowns 3y | |
|---|---|
| Max DD | 85.07% |
| Mean DD | 40.43% |
| Median DD | 42.99% |
Description: QTRX Quanterix October 28, 2025
Quanterix Corporation (NASDAQ: QTRX) is a U.S.–based life-sciences firm that designs, manufactures, and markets digital immunoassay platforms aimed at advancing precision health across research and diagnostic markets in North America, Europe, the Middle East, Africa, and the Asia-Pacific.
The company’s product suite centers on its Simoa (Single Molecule Array) technology, including the HD-X instrument for ultra-sensitive protein detection, the SR-X platform that extends Simoa to a broader set of applications, and the SP-X system that enables multiplex chemiluminescent immunoassays on a planar array. Complementary consumables-beads, capture/detector reagents, enzymes, substrates-and a full line of replacement parts and antibodies are sold alongside contract-research services such as sample testing, custom assay development, and LDT (Laboratory-Developed Test) support.
Quanterix focuses on high-growth therapeutic areas-neurology, oncology, immunology, and inflammation-and serves academic and governmental labs, pharmaceutical and biotechnology firms, and contract-research organizations through direct field sales, support teams, and a network of distributors and agents.
The firm was incorporated in 2007 (formerly Digital Genomics, Inc.) and is headquartered in Billerica, Massachusetts. As of the latest filing, QTRX’s market capitalization is roughly $2.5 billion, FY 2023 revenue reached about $140 million (≈ 30 % YoY growth), and its Simoa platform is estimated to command ~15 % of the ultra-sensitive assay market-a segment benefitting from the 8 % annual rise in global biotech R&D spending.
For a data-driven valuation framework, the ValueRay analysis of QTRX provides the metrics you need to gauge upside potential.
QTRX Stock Overview
| Market Cap in USD | 249m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2017-12-07 |
| Return 12m vs S&P 500 | -55.6% |
| Analyst Rating | 3.75 of 5 |
QTRX Dividends
Currently no dividends paidQTRX Growth Ratios
| CAGR 3y | -21.37% |
| CAGR/Max DD Calmar Ratio | -0.25 |
| CAGR/Mean DD Pain Ratio | -0.53 |
| Current Volume | 1043.3k |
| Average Volume | 496.2k |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-95.7m TTM) > 0 and > 6% of Revenue (6% = 7.74m TTM) |
| FCFTA -0.15 (>2.0%) and ΔFCFTA -5.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 120.9% (prev 247.7%; Δ -126.9pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.15 (>3.0%) and CFO -65.1m > Net Income -95.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (46.1m) change vs 12m ago 19.80% (target <= -2.0% for YES) |
| Gross Margin 51.07% (prev 55.99%; Δ -4.92pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 30.17% (prev 32.46%; Δ -2.29pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -19.64 (EBITDA TTM -93.3m / Interest Expense TTM -5.43m) >= 6 (WARN >= 3) |
Altman Z'' -7.93
| (A) 0.35 = (Total Current Assets 233.3m - Total Current Liabilities 77.4m) / Total Assets 444.1m |
| (B) -1.25 = Retained Earnings (Balance) -554.1m / Total Assets 444.1m |
| warn (B) unusual magnitude: -1.25 — check mapping/units |
| (C) -0.25 = EBIT TTM -106.6m / Avg Total Assets 427.6m |
| (D) -4.28 = Book Value of Equity -554.9m / Total Liabilities 129.6m |
| Total Rating: -7.93 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 17.90
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -44.35% = -5.0 |
| 3. FCF Margin -52.89% = -7.50 |
| 4. Debt/Equity 0.13 = 2.49 |
| 5. Debt/Ebitda -0.02 = -2.50 |
| 6. ROIC - WACC (= -46.41)% = -12.50 |
| 7. RoE -30.53% = -2.50 |
| 8. Rev. Trend 40.73% = 3.05 |
| 9. EPS Trend -62.91% = -3.15 |
What is the price of QTRX shares?
Over the past week, the price has changed by +12.11%, over one month by -3.53%, over three months by +15.96% and over the past year by -48.66%.
Is Quanterix a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of QTRX is around 4.22 USD . This means that QTRX is currently overvalued and has a potential downside of -26.48%.
Is QTRX a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the QTRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6 | 4.5% |
| Analysts Target Price | 6 | 4.5% |
| ValueRay Target Price | 5 | -13.4% |
QTRX Fundamental Data Overview November 15, 2025
P/S = 1.9086
P/B = 0.7782
Beta = 1.044
Revenue TTM = 129.0m USD
EBIT TTM = -106.6m USD
EBITDA TTM = -93.3m USD
Long Term Debt = 40.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.41m USD (from shortTermDebt, last quarter)
Debt = 40.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.82m USD (from netDebt column, last quarter)
Enterprise Value = 153.8m USD (248.5m + Debt 40.1m - CCE 134.8m)
Interest Coverage Ratio = -19.64 (Ebit TTM -106.6m / Interest Expense TTM -5.43m)
FCF Yield = -44.35% (FCF TTM -68.2m / Enterprise Value 153.8m)
FCF Margin = -52.89% (FCF TTM -68.2m / Revenue TTM 129.0m)
Net Margin = -74.17% (Net Income TTM -95.7m / Revenue TTM 129.0m)
Gross Margin = 51.07% ((Revenue TTM 129.0m - Cost of Revenue TTM 63.1m) / Revenue TTM)
Gross Margin QoQ = 42.65% (prev 46.12%)
Tobins Q-Ratio = 0.35 (Enterprise Value 153.8m / Total Assets 444.1m)
Interest Expense / Debt = 30.88% (Interest Expense 12.4m / Debt 40.1m)
Taxrate = 6.89% (-2.48m / -36.0m)
NOPAT = -99.2m (EBIT -106.6m * (1 - 6.89%)) [loss with tax shield]
Current Ratio = 3.02 (Total Current Assets 233.3m / Total Current Liabilities 77.4m)
Debt / Equity = 0.13 (Debt 40.1m / totalStockholderEquity, last quarter 314.5m)
Debt / EBITDA = -0.02 (negative EBITDA) (Net Debt 1.82m / EBITDA -93.3m)
Debt / FCF = -0.03 (negative FCF - burning cash) (Net Debt 1.82m / FCF TTM -68.2m)
Total Stockholder Equity = 313.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.54% (Net Income -95.7m / Total Assets 444.1m)
RoE = -30.53% (Net Income TTM -95.7m / Total Stockholder Equity 313.4m)
RoCE = -30.15% (EBIT -106.6m / Capital Employed (Equity 313.4m + L.T.Debt 40.1m))
RoIC = -31.66% (negative operating profit) (NOPAT -99.2m / Invested Capital 313.4m)
WACC = 14.75% (E(248.5m)/V(288.6m) * Re(12.49%) + D(40.1m)/V(288.6m) * Rd(30.88%) * (1-Tc(0.07)))
Discount Rate = 12.49% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.26%
Fair Price DCF = unknown (Cash Flow -68.2m)
EPS Correlation: -62.91 | EPS CAGR: -41.57% | SUE: -1.81 | # QB: 0
Revenue Correlation: 40.73 | Revenue CAGR: 17.76% | SUE: 0.91 | # QB: 1
Additional Sources for QTRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle